Uso do trastuzumabe na gravidez

O uso do trastuzumabe, anticorpo antimonoclonal contra o receptor do fator de crescimento epidermico HER-2, tem sido utilizado no tratamento do carcinoma mamario de pacientes que superexpressam esta proteina. Relatos de casos divergem quanto a presenca ou ausencia de efeitos adversos na gravidez. Quando presentes, os mais encontrados no feto foram: oligo ou anidrâmnio, insuficiencia renal, sindrome de angustia respiratoria e obito fetal/neonatal. Esta revisao discutiu as vias etiopatologicas possiveis deste farmaco em causar tais efeitos e sugeriu uma propedeutica de seguimento dessas pacientes. The use of trastuzumab, a monoclonal antibody against human epidermal growth factor receptor type 2, has been a useful therapy in the treatment of breast cancer patients that overexpress such protein. Published case reports with different results regarding the presence or absence of adverse effects in pregnancy are shown. If present, the most reported ones were: oligo or anydramnios, renal insufficiency, respiratory distress syndrome, and fetal/neonatal death. This review discussed the ethiopathologic pathways of this drug in causing such effects and suggested a follow-up protocol for these patients.